Dyne Therapeutics (NASDAQ:DYN) Shares Cross Below 50 Day Moving Average Following Insider Selling

Dyne Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Dyne shares fell below their 50-day moving average, trading at $16.70 versus the $16.81 average; the stock was reported down 2.7%.
  • CFO Erick Lucera sold 1,991 shares for about $33,489 to cover tax withholding on vested equity awards, reducing his holdings by 1.66%.
  • Analyst views are mixed, with a “Moderate Buy” consensus and an average price target of $31.29. Dyne also missed quarterly EPS expectations, reporting a loss of $1.06 per share versus the $0.91 loss analysts forecast.
  • MarketBeat previews top five stocks to own in December.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) shares passed below its 50-day moving average during trading on Monday following insider selling activity. The stock has a 50-day moving average of $16.81 and traded as low as $16.49. Dyne Therapeutics shares last traded at $16.70, with a volume of 1,849,642 shares.

Specifically, CFO Erick Lucera sold 1,991 shares of the business's stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $16.82, for a total transaction of $33,488.62. Following the completion of the sale, the chief financial officer owned 117,775 shares of the company's stock, valued at approximately $1,980,975.50. The trade was a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Analysts Set New Price Targets

A number of brokerages have commented on DYN. Morgan Stanley reduced their price target on Dyne Therapeutics from $45.00 to $36.00 and set an "overweight" rating for the company in a research report on Wednesday, September 9th. Oppenheimer cut Dyne Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $40.00 to $15.00 in a research report on Wednesday, October 28th. Piper Sandler reaffirmed an "overweight" rating and set a $47.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, September 29th. HC Wainwright cut their price objective on Dyne Therapeutics from $50.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, September 30th. Finally, Robert W. Baird reduced their target price on shares of Dyne Therapeutics from $30.00 to $26.00 and set an "outperform" rating for the company in a report on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $31.29.

Check Out Our Latest Research Report on DYN

Dyne Therapeutics Trading Down 2.7%

The stock has a market cap of $3.13 billion, a P/E ratio of -4.60 and a beta of 1.22. The stock's 50-day moving average is $16.81 and its two-hundred day moving average is $19.32. The company has a debt-to-equity ratio of 0.21, a current ratio of 12.99 and a quick ratio of 12.99.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.15). During the same quarter in the prior year, the company posted ($0.76) EPS. Equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.81 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at $275,500,000. Jupiter Topco LLC bought a new stake in Dyne Therapeutics in the second quarter worth $266,634,000. Bank of America Corp DE bought a new stake in Dyne Therapeutics in the second quarter worth $49,604,000. Palo Alto Investors LP purchased a new position in Dyne Therapeutics during the second quarter worth $36,591,441. Finally, Perceptive Advisors LLC boosted its stake in Dyne Therapeutics by 34.2% during the first quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company's stock worth $84,646,000 after buying an additional 1,189,895 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company's programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Dyne Therapeutics Right Now?

Before you consider Dyne Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.

While Dyne Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines